Digestive Diseases and Sciences

, Volume 59, Issue 5, pp 1048–1054 | Cite as

Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000

  • Reena J. Salgia
  • Amit G. Singal
  • Sherry Fu
  • Shawn Pelletier
  • Jorge A. Marrero
Original Article



The incidence of cholangiocarcinoma (CCA) continues to rise. Orthotopic liver transplantation (OLT) can be used for selected patients with localized but unresectable hilar CCA. Although initial post-OLT survival rates were poor, outcomes after introduction of the Mayo Clinic protocol have been more promising and there has been increased interest in OLT for CCA nationally.


The aim of this study is to determine post-transplant survival and prognostic factors for patients undergoing OLT for CCA.


A retrospective analysis of all patients with CCA listed nationwide for OLT between October 1987 and May 2008 was performed using the Scientific Registry of Transplant Recipients database. Survival curves were generated using the Kaplan–Meier method and compared using log-rank test.


Of 595 patients with CCA listed for OLT, 359 (60.3 %) underwent OLT. Median age at OLT was 49 years, 66 % were male and 91 % were Caucasian. The median follow-up time was 2 years. There has been an increasing number of liver transplants performed for CCA since 2000. The 1- and 5-year probability of survival was 85.8 and 51.4 %, respectively. On multivariate analysis, significant prognostic factors for decreased post-OLT survival included transplant before 2000 (HR 11.25, 95 % CI 1.28–98.7) and acute cellular rejection (HR 5.64, 95 % CI 1.14–27.8).


Survival after transplant for CCA has improved over time, and OLT is being used more frequently in the treatment of CCA. Significant predictors of post-OLT survival include a history of acute rejection and date of transplant in relation to the publication of Mayo protocol results.


Cholangiocarcinoma Liver transplant Outcomes Survival 


  1. 1.
    Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125.PubMedCrossRefGoogle Scholar
  2. 2.
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–477.PubMedCrossRefGoogle Scholar
  3. 3.
    Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–820.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–615.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Singal AG, Rakoski MO, Salgia RJ, et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010;31:625–633.PubMedCrossRefGoogle Scholar
  6. 6.
    Ahrendt SA, Cameron JL, Pitt HA. Current management of patients with perihilar cholangiocarcinoma. Adv Surg. 1996;30:427–452.PubMedGoogle Scholar
  7. 7.
    Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg. 1998;227:70–79.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther. 2006;23:1287–1296.PubMedCrossRefGoogle Scholar
  9. 9.
    Guthrie CM, Haddock G, De Beaux AC, Garden OJ, Carter DC. Changing trends in the management of extrahepatic cholangiocarcinoma. Br J Surg. 1993;80:1434–1439.PubMedCrossRefGoogle Scholar
  10. 10.
    Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215:31–38.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma—a population-based study. Ann Surg Oncol. 2008;15:600–608.PubMedCrossRefGoogle Scholar
  12. 12.
    Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010;16:930–942.PubMedCrossRefGoogle Scholar
  13. 13.
    Castaldo ET, Pinson CW. Liver transplantation for non-hepatocellular carcinoma malignancy. HPB (Oxf). 2007;9:98–103.CrossRefGoogle Scholar
  14. 14.
    Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110:726–735.PubMedGoogle Scholar
  15. 15.
    Singal A, Welling TH, Marrero JA. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther. 2009;9:491–502.PubMedCrossRefGoogle Scholar
  16. 16.
    De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6:309–316.PubMedCrossRefGoogle Scholar
  17. 17.
    Gores GJ, Heimbach JK, Rosen CB. Liver transplantation for non-hepatocellular carcinoma malignancies. Liver Transpl. 2010;16:S22–S25.CrossRefGoogle Scholar
  18. 18.
    Murad D, Kim WR, Harnois DM, et al. Effects of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88–98.CrossRefGoogle Scholar
  19. 19.
    Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633–1637.PubMedCrossRefGoogle Scholar
  20. 20.
    Becker NS, Rodriguez JA, Barshes NR, O’Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg. 2008;12:117–122.PubMedCrossRefGoogle Scholar
  21. 21.
    Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006;82:1703–1707.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Reena J. Salgia
    • 1
  • Amit G. Singal
    • 2
  • Sherry Fu
    • 1
    • 4
  • Shawn Pelletier
    • 3
  • Jorge A. Marrero
    • 2
    • 5
  1. 1.Department of Internal Medicine, Taubman Medical CenterUniversity of MichiganAnn ArborUSA
  2. 2.Department of Internal MedicineUniversity of Texas SouthwesternDallasUSA
  3. 3.Department of General SurgeryUniversity of VirginiaCharlottesvilleUSA
  4. 4.Simpson Memorial InstituteAnn ArborUSA
  5. 5.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations